行业并购整合机遇受关注，港股创新药ETF（159567）10月以来累计吸金逾16亿元，基金份额突破100亿份创历史新高

Core Viewpoint - The Hong Kong stock market is experiencing fluctuations, but the innovative pharmaceutical sector is showing resilience with notable gains in specific stocks and ETFs [1] Group 1: Market Performance - The Hong Kong innovative pharmaceutical sector saw stocks like Ascentage Pharma-B, Kelun-Biotech, and Hengrui Medicine rise slightly despite market adjustments [1] - The Hong Kong Innovative Drug ETF (159567) opened higher, initially rising by 0.71% before retreating with the market [1] Group 2: Fund Flows and Growth - Since October, the Hong Kong Innovative Drug ETF (159567) has seen an increase of 1.928 billion shares, with a cumulative net inflow of over 1.6 billion yuan, surpassing 10 billion shares for the first time [1] - Analysts indicate that China is becoming a significant player in global innovative drug development, with increasing overseas licensing transactions driving sector growth [1] Group 3: Future Outlook - The pharmaceutical industry is entering a critical phase characterized by "innovation realization + global layout," supported by population and domestic demand, as well as comprehensive manufacturing capabilities [1] - By 2026, there are opportunities to focus on innovative commercialization, global breakthroughs, policy optimization, and industry mergers and acquisitions [1] Group 4: Investment Opportunities - The Hong Kong Innovative Drug ETF tracks the CSI Hong Kong Stock Connect Innovative Drug Index, reflecting the performance of listed companies in the innovative drug sector [1] - Investors can access the Hong Kong Innovative Drug ETF through linked funds (Class A: 023929, Class C: 023930) to capitalize on the upward potential of the sector [1]